自动氧滴定与恒定氧流量对COPD患者步行能力的影响:随机对照双盲交叉试验
结果显示ATOS组步行时间显著延长(中位效应+144.5秒,95%CI 54-241.5,p<0.001),等时点SpO2更高,运动终点PaO2更高且呼吸困难评分更低,PCO2无差异。
要点
- ATOS较运动滴定CFOS显著延长COPD患者步行耐力时间。
- ATOS提高等时点SpO2和运动终点PaO2,不增加PCO2。
- ATOS改善运动终点呼吸困难评分。
核心结论
- 在低氧血症的重度COPD患者中,使用ATOS可显著改善步行耐力时间、SpO2、PaO2和呼吸困难,且不影响PCO2。
主要发现
- ATOS组步行时间较CFOS组显著延长,中位效应+144.5秒(95%CI 54-241.5),p<0.001。
- 等时点SpO2在ATOS组显著更高(+3%,95%CI 1-4),p<0.001;TcPCO2、呼吸频率和心率无显著差异。
- 运动终点PaO2在ATOS组显著更高(+8.85 mm Hg,95%CI 6.35-11.9),呼吸困难评分显著更低(-0.5分,95%CI -1.0至-0.5),均p<0.001;PCO2无显著差异。
关键数值与推荐
- ATOS目标SpO2为92%。
- 纳入患者中位年龄66岁(IQR 59-70),FEV1占预计值28.8%(IQR 24.8-35.1),PO2 54.7 mm Hg(IQR 51.0-57.7),PCO2 44.2 mm Hg(IQR 38.2-47.8)。
临床怎么用
- 对于运动时低氧血症的重度COPD患者,可考虑使用自动滴定氧系统以改善步行耐力和氧合,但需注意本试验为交叉设计,临床推广需结合个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: In patients with COPD, oxygen (O2)-supplementation via a constant flow oxygen system (CFOS) can result in insufficient oxygen saturation (SpO2 <90%) during exercise. An automatically titrating O2-system (ATOS) has been shown to be beneficial compared with an untitrated CFOS, however, it is unknown if ATOS is superior to CFOS, titrated during exercise as stipulated by guidelines. The aim was to investigate the effects of ATOS compared with titrated CFOS on walking capacity in people with hypoxaemic COPD. METHODS: Fifty participants completed this prospective randomised controlled, double-blind, crossover trial. Participants performed two endurance shuttle walk tests (ESWTs) with: (1) exercise titrated CFOS (ESWTCFOS) and (2) ATOS targeting an SpO2 of 92% (ESWTATOS). Primary outcome measure was walking time. Secondary measures were SpO2, transcutaneous-PCO2 (TcPCO2), respiratory rate (RR), heart rate (HR) at isotime (end of shortest ESWT) with blood gases and dyspnoea at rest and end exercise. RESULTS: Participants (median (IQR): age 66 (59, 70) years, FEV1 28.8 (24.8, 35.1) % predicted, PO2 54.7 (51.0, 57.7) mm Hg, PCO2 44.2 (38.2, 47.8) mm Hg) walked significantly longer with ESWTATOS in comparison to ESWTCFOS (median effect (95% CI) +144.5 (54 to 241.5) s, p<0.001). At isotime, SpO2 was significantly higher (+3 (95% CI 1 to 4) %, p<0.001) with ATOS while TcPCO2, RR and HR were comparable. End exercise, PO2 (+8.85 (95% CI 6.35 to 11.9) mm Hg) and dyspnoea (-0.5 (95% CI -1.0 to -0.5) points) differed significantly in favour of ATOS (each p<0.001) while PCO2 was comparable. CONCLUSION: In patients with hypoxaemia with severe COPD the use of ATOS leads to significant, clinically relevant improvements in walking endurance time, SpO2, PO2 and dyspnoea with no impact on PCO2. TRIAL REGISTRATION NUMBER: NCT03803384.
引用
- Schneeberger T, Jarosch I, Leitl D, et al. Automatic oxygen titration versus constant oxygen flow rates during walking in COPD: a randomised controlled, double-blind, crossover trial. Thorax. 2021. PMID: 34656996. doi:10.1136/thoraxjnl-2020-216509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。